Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Multiple Myeloma (RRMM)”

157 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 157 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06171685
What this trial is testing

MMRC Horizon One: RRMM (MMRC-099)

Who this might be right for
Relapse Multiple MyelomaRefractory Multiple Myeloma
Multiple Myeloma Research Consortium 300
Large-scale testing (Phase 3)Active Not RecruitingNCT05552976
What this trial is testing

Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb 606
Testing effectiveness (Phase 2)UnknownNCT04891744
What this trial is testing

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Who this might be right for
Multiple Myeloma
Li Zheng 48
Testing effectiveness (Phase 2)WithdrawnNCT05408026
What this trial is testing

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Early research (Phase 1)Active Not RecruitingNCT05286229
What this trial is testing

Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 8
Testing effectiveness (Phase 2)Looking for participantsNCT06952075
What this trial is testing

GR1803 Injection in Patients With RRMM

Who this might be right for
Multiple Myleoma
Genrix (Shanghai) Biopharmaceutical Co., Ltd. 30
Large-scale testing (Phase 3)Study completedNCT03110562
What this trial is testing

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc 402
Early research (Phase 1)UnknownNCT04677452
What this trial is testing

Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM

Who this might be right for
Safety and Efficacy
The First Affiliated Hospital of Soochow University 24
Testing effectiveness (Phase 2)Looking for participantsNCT06297226
What this trial is testing

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 230
Large-scale testing (Phase 3)Active Not RecruitingNCT05028348
What this trial is testing

Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 117
Early research (Phase 1)Not Yet RecruitingNCT07622862
What this trial is testing

Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma RefractoryMultiple Myeloma Progression
Zhongshan Hospital (Xiamen), Fudan University 16
Testing effectiveness (Phase 2)Ended earlyNCT06160609
What this trial is testing

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline 9
Early research (Phase 1)Ended earlyNCT04401020
What this trial is testing

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Who this might be right for
Neoplasm Malignant
Sanofi 47
Testing effectiveness (Phase 2)Looking for participantsNCT06832865
What this trial is testing

ELISA in Relapsed/Refractory MM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)Relapsed Refractory Multiple Myeloma
Massachusetts General Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT07681596
What this trial is testing

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
AstraZeneca 101
Not applicableStudy completedNCT05217082
What this trial is testing

A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 35
Very early researchNot Yet RecruitingNCT07234721
What this trial is testing

SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 9
Testing effectiveness (Phase 2)Looking for participantsNCT06103838
What this trial is testing

18F-Fluciclovine PET/CT in Multiple Myeloma

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Looking for participantsNCT06920251
What this trial is testing

Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Seoul National University Hospital 40
Large-scale testing (Phase 3)Looking for participantsNCT06615479
What this trial is testing

Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 440
Next Page